Future studies are warranted to define whether the efficacy of CIT is dependent on certain ICI to recruit immune cells into tumor tissues (like CX3CR1+CD8 effector T cells) or to expand local tumor-infiltrating immune cells to reject tumors. This evidence concerns the gene CD8A and neoplasm.